association

Full identifier: http://purl.org/np/RAwlUKOkdB0hlnEFIKDZZnj3Llnpi16vL85c7lnRd7t4w#association

Assigned to 1 class:

Minted in Nanopublication

 RAwlUKOkdB comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAwlUKOkdB...#association association https://w3id.org/biolink/vocab/has_population_context has_population_context This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAwlUKOkdB...#context context .
This is a local identifier that was minted when the nanopublication was created. http://purl.org/np/RAwlUKOkdB...#context context http://www.w3.org/2000/01/rdf-schema#label label "adults" .
This is the identifier for this whole nanopublication. http://purl.org/np/RAwlUKOkdB... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAhNHZw6Ur... RAhNHZw6Ur .

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Escitalopram showed favorable pharmacokinetics and good tolerability. It is the most 5-HT-selective among SSRIs, with little or no affinity for other transmitter transporters or receptors [59]. Compared to other SSRIs, escitalopram may have weak or minimal interactions with the cytochrome P450 system [60, 61]. In a randomized, double-blind, placebo-controlled 24-week trial in OCD, escitalopram (20 mg/day) was associated with an increase in response rate compared to placebo after 12 weeks. Other placebo-controlled studies consistently showed escitalopram-related treatment response [25, 30]. 20 mg/day escitalopram has also been associated with better OCD symptom remission compared to 40 mg/day paroxetine or placebo at week 12 [30]. Three different escitalopram dosages (5, 10, and 20 mg/day) were compared with a fixed, 20 mg/day dose of paroxetine in a 12-week study, in which escitalopram showed both greater efficacy and better tolerability [62].
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Vincent Emonet
2022-09-16T11:53:46.825Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)